Company intelligence / Profile preview

Berry Genomics

Beijing, Beijing, Chinaberrygenomics.com ↗

Ownership: Private
Employees: ~1500
Development stage: Commercial

Overview

Berry Genomics pioneered the first NGS-based non-invasive prenatal test in China. The company offers a broad portfolio of commercialized genetic tests for prenatal screening, hereditary cancers, and adult-onset diseases. It leads global clinical research on early liver cancer detection using advanced genomics. Ongoing R&D includes third-generation sequencing applications.

Therapeutic areas: OncologyRare DiseasesWomen's Health
Modalities: Genetic testing (NGS-based)Medical device (diagnostic)Gene therapy (early-stage involvement)Sequencing-based integrated solutions
Industry: Molecular Diagnostics

Partnerships

Sanomics Limited with Professor Tony Mok/CUHKInvestment partnership with CircleDNACollaborations with over 6000 hospitals/research institutions worldwide

Beyond the preview

Go deeper on Berry Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Berry Genomics.

Explore the full profile